Women with a confirmed diagnosis of endometriosis (diagnosed by laparoscopy or imaging)..
Conditions
Interventions
Intervention 1: Intervention group: Women with confirmed endometriosis (diagnosed by laparoscopy or imaging) will be divided into two groups. Group 1: dienogest alone (dose 2 mg daily) orally, once da
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Age 18 to 45 years. No severe comorbidities (such as liver or kidney disease) No use of hormone therapy in the past 3 months Diagnosis of moderate to severe endometriosis.
Exclusion criteria
Exclusion criteria: Pregnancy or planning to become pregnant during the study. Inaccessibility of the patient for follow-up of treatment outcome Allergy to dienogest or zinc. Unwillingness to continue participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining the average pain score of endometriosis patients in the two groups of dienogest alone and dienogest combined with zinc. Timepoint: Group 1: Dienogest alone (2 mg daily dose) orally and Group 2: Dienogest 2 mg daily dose + Zinc (50 mg daily dose) orally, once daily. Both groups will be followed for 6 months (at intervals of 1, 3 and 6 months). Patients will be visited by a gynecologist at monthly intervals to assess pain . At the end of the fourth month, they will be re-evaluated for pain score. Method of measurement: VAS pain measurement tool.;Determining the average quality of life score in endometriosis patients in two groups: dienogest alone and dienogest combined with zinc. Timepoint: Group 1: Dienogest alone (2 mg daily dose) orally and Group 2: Dienogest 2 mg daily dose + Zinc (50 mg daily dose) orally, once daily. Both groups will be followed up for 6 months (at intervals of 1, 3 and 6 months). Patients will be evaluated by the researcher at monthly intervals for quality of life assessment during gynecological visits. At the end of the fourth month, they will be re-evaluated for quality of life score. Method of measurement: Endometriosis-related quality of life questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Ahmadi
Hamedan University of Medical Sciences
Outcome results
None listed